Skip to main content
Premium Trial:

Request an Annual Quote

Eclipse Bioinnovations 3' and 5' End-Seq

Eclipse Bioinnovations has launched its 3' and 5' End-Seq Kits.

End-Seq can facilitate the precise identification of untranslated regions (UTR) for RNA therapeutics targeting and can be used as a tool for identifying UTR biomarkers associated with disease. The 3' End-Seq kit can quantify the relative usage of polyadenylation sites across samples while 5' End-Seq kit can quantify the relative usage of transcription start sites. Both kits can indicate transcript isoform presence in annotated transcriptomes and help predict binding factor motifs more reliably.